Michel Habib
Angel Investor @ HBL Hadasit Bio Holdings
Tel Aviv, Israel
Michel Habib is a Series A investor at HBL Hadasit Bio Holdings in Tel Aviv focused on Medical and Health Care. Managing partner at Agate Venture, Founder & CEO Matar Capital Advisors. Former Director Business Development, Elron Electronic Industries, part of the IDB group (NASDAQ ELRN). Led Elron's Medical Device sector investments, served on the BOD of Elbit Vision Systems, Nulens, AMT, 3DV Systems & others. Former Head of investmentbanking Israel at ING Barings, the investment banking arm of ING Group. Vice President Investment Banking, Cukierman & Co., where he managed private placements and IPOs in Europe. Israel's Economic Consul in Boston, & Commercial Attache to South Korea. B.Sc. in Aeronautical Engineering from the Technion - Israel Institute of Technology. Member of the Technion Alumni 100 Club.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Michel Habib invests in
Stages Michel Habib invests in
Countries Michel Habib invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (50%)
- Health Care 2 (50%)
- Apps 1 (25%)
- Mobile 1 (25%)
- Internet 1 (25%)
Stage
- Series A 1 (25%)
- Series C 1 (25%)
- Venture - Series Unknown 1 (25%)
Country
- Israel 2 (50%)
- Switzerland 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Wisdo is an AI-powered Social Health platform harnessing the power of data and meaningful connections to improve health. | $5M / Series A / Jan 05, 2023 | ||
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M / Venture - Series Unknown / Jun 16, 2021 | ||
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $18M / Venture - Series Unknown / Feb 25, 2020 | ||
| Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland. | Series C / Oct 09, 2012 |
Co-Investors
About HBL Hadasit Bio Holdings
Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.
HBL Hadasit Bio Holdings Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Rafi Hofstein
President & CEO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michel Habib invest in?
Michel Habib invests primarily in Medical, Health Care and Apps startups, most often at Series A and Series C stage. Most of the 4 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Michel Habib?
Public channels for Michel Habib include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michel Habib last invest?
The most recent investment recorded for Michel Habib closed in Jan 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
